{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-25-000100","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.884125+00:00","generated_at":"2026-05-17T20:34:23.549340+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pacira Q2 2025 revenue $181.1M, GAAP net loss $4.8M; guidance updated, legal win $28.3M","bullets":["Total revenues $181.1M (+2% YoY); EXPAREL $142.9M, ZILRETTA $31.3M, iovera° $5.6M.","GAAP net loss $4.8M ($0.11/share) vs net income $18.9M in Q2 2024; non-GAAP net income $36.0M.","Received $28.3M from favorable court ruling on EXPAREL royalty repayment from RDF in July 2025.","New $300M five-year revolving credit facility replaces prior term loan; reduces interest expense 60bps in 2026.","2025 guidance: revenue narrowed to $730M-$750M; non-GAAP gross margin raised to 78-80%."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-25-000100","json":"https://secwatch.observer/filing/0001396814-25-000100.json","markdown":"https://secwatch.observer/filing/0001396814-25-000100.md","text":"https://secwatch.observer/filing/0001396814-25-000100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000100/0001396814-25-000100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000100/pcrx-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:34:23.549340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}